Demonstration Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Panitumumab
found
9 matches
Links
Link to Drug Section
Link to document
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
